In line with Recommendation 24* of the National Cancer Strategy 2017-2026 the NCCP are developing NCCP National Patient Pathways for individual haematological malignancies.
These Pathways are developed in collaboration with the appropriate NCCP SACT Clinical Advisory Group (CAG) under the governance of the NCCP National Haemato-oncology Clinical Leads Group
The NCCP National Patient Pathways will be added to this webpage when approved.
NCCP National Haemato-oncology Adult Patient Pathway: Acute Lymphoblastic Leukaemia (ALL)/ Acute Lymphoblastic Lymphoma (LBL)
NCCP National Haemato-oncology Adult Patient Pathway: Acute Myeloid Leukaemia (AML)
*Recommendation 24: The NCCP will develop appropriate MDT, centralisation and treatment arrangements to meet the diverse needs of patients with haematological cancers.